Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Other Non-Current Liabilities (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $147000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 54.63% to $147000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $147000.0, a 54.63% decrease, with the full-year FY2025 number at $147000.0, down 54.63% from a year prior.
  • Other Non-Current Liabilities was $147000.0 for Q4 2025 at PROCEPT BioRobotics, down from $576000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q3 2023 to a low of $147000.0 in Q4 2025.
  • A 5-year average of $766529.4 and a median of $479000.0 in 2024 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 829.5% in 2023, then crashed 74.23% in 2024.
  • PROCEPT BioRobotics' Other Non-Current Liabilities stood at $200000.0 in 2021, then surged by 789.5% to $1.8 million in 2022, then plummeted by 70.94% to $517000.0 in 2023, then crashed by 37.33% to $324000.0 in 2024, then tumbled by 54.63% to $147000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Other Non-Current Liabilities are $147000.0 (Q4 2025), $576000.0 (Q3 2025), and $223000.0 (Q2 2025).